IGF1R and adrenal cortex carcinoma: The current study confirms that linsitinib (OSI-906), an IGF1R/IR inhibitor, inhibits the proliferation of the human ACC cell lines H295R and HAC15 in vitro already at a concentration lower than the concentrations reached in vivo in humans (about 5 × 10−6 M).